argenx (NASDAQ:ARGX) Raised to “Buy” at ValuEngine

argenx (NASDAQ:ARGX) was upgraded by equities research analysts at ValuEngine from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Monday, February 4th.

A number of other research firms have also recently weighed in on ARGX. Evercore ISI assumed coverage on shares of argenx in a research report on Monday, October 15th. They set an “outperform” rating and a $110.00 price objective for the company. Wedbush reiterated an “outperform” rating and issued a $125.00 target price (down from $130.00) on shares of argenx in a research report on Monday, November 5th. Piper Jaffray Companies increased their target price on shares of argenx from $154.00 to $161.00 and gave the company an “overweight” rating in a research report on Tuesday, December 4th. Zacks Investment Research upgraded shares of argenx from a “hold” rating to a “buy” rating and set a $112.00 price objective for the company in a research report on Wednesday, December 12th. Finally, Morgan Stanley assumed coverage on shares of argenx in a research report on Friday, January 4th. They set an “overweight” rating and a $140.00 price objective for the company. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. argenx presently has a consensus rating of “Buy” and a consensus target price of $140.91.

Shares of ARGX stock traded up $1.30 during trading hours on Monday, hitting $134.59. The company’s stock had a trading volume of 174,226 shares, compared to its average volume of 171,606. argenx has a 12-month low of $63.81 and a 12-month high of $135.58. The company has a market capitalization of $4.08 billion, a P/E ratio of -96.14 and a beta of 1.20.

Institutional investors have recently modified their holdings of the stock. United Services Automobile Association lifted its stake in argenx by 78.9% in the second quarter. United Services Automobile Association now owns 32,200 shares of the company’s stock worth $2,668,000 after acquiring an additional 14,200 shares during the last quarter. DekaBank Deutsche Girozentrale acquired a new stake in argenx during the third quarter worth approximately $3,746,000. Artal Group S.A. raised its holdings in argenx by 23.3% during the third quarter. Artal Group S.A. now owns 185,000 shares of the company’s stock worth $14,030,000 after purchasing an additional 35,000 shares in the last quarter. Gabelli Funds LLC acquired a new stake in argenx during the third quarter worth approximately $2,844,000. Finally, Dimensional Fund Advisors LP raised its holdings in argenx by 22.1% during the second quarter. Dimensional Fund Advisors LP now owns 7,559 shares of the company’s stock worth $626,000 after purchasing an additional 1,366 shares in the last quarter. Institutional investors own 65.55% of the company’s stock.

About argenx

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Recommended Story: Marijuana Stocks Future Looks Bright

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply